X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pharma: Partners in growth? - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Apr 17, 2006

    Pharma: Partners in growth?

    While pharma companies seem to have left the demons of the past year well behind them, challenges still abound in the global generics arena, in the domestic market and even in discovery research. And this is due to changing fundamentals and business dynamics of the sector. One is the introduction of the product patent law. The other is the increased competition and brutal price erosion in the generics market.

    Keeping this in mind, pharma companies are looking to forge alliances with global innovators in various aspects of business, be it research, generics or new product launches. In fact, even the stock markets have perceived these 'partnerships' in a favourable light. In this write-up, we shall attempt to find out why.

    Alliance with global pharma majors in...
    Discovery research: Considering that discovery research is a high-risk, high-return business, Indian pharma companies have been collaborating with global pharma companies in light of the huge investments involved and uncertainty in the outcome. To cite examples, Ranbaxy's anti-malarial molecule, which is currently undergoing Phase II clinical trials, is being developed in collaboration with Medicines for Malaria Venture. Out-licensing of molecules in return for milestone payments is also another commonly followed approach to mitigate the high costs involved in NCE (new chemical entity) research. Also, Glenmark, whose molecule 'Oglemilast', which the company out-licensed to the US-based Forest Labs, has generated considerable interest on the bourses in the past one year. Dr. Reddy's formation of a separate company for carrying out clinical trials has also been touted as a smart move and is expected to contribute to margin expansion going forward.

    Contract research: Contract research is also tipped to gain ground in India after the introduction of the product patent law. With considerable pressure on global pharma majors to cut back their R&D costs, a majority of them are looking to shift some of their R&D work to low-cost destinations like India. For example, Biocon has forayed into the custom research business with the formation of two subsidiaries, Syngene and Clinigene. While the contribution of this business to overall revenues (12%) is smaller in comparison to its biopharmaceuticals business (77%), it clocked an impressive 69% YoY and 47% YoY growth in FY05 and 9mFY06 indicating the potential for growth in this field.

    Generics: While much as been said about authorised generics and the bane it is to generic companies aiming for that increasingly elusive 180-day exclusivity period, there is also a silver lining. This holds true if it is an Indian pharma company authorised to sell the generic version. Dr. Reddy's has entered into an authorised generics deal with Merck for the latter's drug 'Simvastatin' and will benefit immensely on the revenue front if the exclusivity period is granted to the challenging company.

    Contract manufacturing: While Ranbaxy and Dr. Reddy's are directly competing in the global generics market, Cipla has entered into alliances with global generic majors such as Ivax, Watson and Mylan to capitalise on the huge generics opportunity in the coming years. In this case, the company is providing low cost bulk drugs to these generic companies and is at the same time obviating any need in incurring expenses in filing ANDAs. This has ensured a relatively stable revenue stream for Cipla as compared to either Ranbaxy or Dr. Reddy's.

    New product launches: In the product patent era, in-licensing agreements with global pharma companies is beneficial in stepping up new product launches in the country. Players such as GSK Pharma, Ranbaxy, Nicholas Piramal, which have a strong marketing and distribution network have an edge over their peers in bagging such deals. Such deals also enable players to widen their product portfolio and consequently boost topline growth.

    To sum up...
    In our view, willingness of Indian pharma companies to bring outside expertise to the table should be construed as a positive step to stabilise revenues and profitability. However, there is also a catch to the situation. This is because as revenues have to be 'shared', the potential upside gets capped. However, considering the volatile performance of some of the domestic pharma majors over the past few years, stability in business has assumed paramount importance. At the end of the day, a solid foundation is what will pave the way for a higher growth and consequently rewarding returns for investors in the long run.

     

     

    Equitymaster requests your view! Post a comment on "Pharma: Partners in growth?". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 21, 2017 10:26 AM

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS